Searchable abstracts of presentations at key conferences in endocrinology

ea0093p4 | Guided Poster Tour 1: Adrenal and Neuroendocrine tumors | EYES2023

Decrease in anticortisolic drug osilodrostat plasma exposure in patients treated with mitotane for an adrenocortical carcinoma

Thomeret Louis , Puszkiel Alicja , Balakirouchenane David , Bouys Lucas , Poirier Jonathan , Berthon Annabel , Ragazzon Bruno , Jouinot Anne , Guignat Laurence , Bessiene Laura , Libe Rossella , Bricaire Leopoldine , Groussin Lionel , Assie Guillaume , Blanchet Benoit , Bonnet-Serrano Fideline , Bertherat Jerome

Introduction: The steroidogenesis inhibitor osilodrostat (OSI), indicated for the medical treatment of endogenous Cushing’s syndrome, exhibits significant interindividual variability regarding the response to treatment (Pivonello et al. 2020). Plasma exposure may contribute to this variability. Our objective was to investigate the effect of concomitant use of mitotane (MIT), a potent inducer of CYP450 (3A4), on circulating OSI concentrations in patients treated f...